M 阳性变构调节剂（PAMs）的优化：VU0476406 的发现，一种用于转化药理学的非人灵长类动物体内工具化合物。
Optimization of M positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.
作者信息
Melancon Bruce J, Wood Michael R, Noetzel Meredith J, Nance Kellie D, Engelberg Eileen M, Han Changho, Lamsal Atin, Chang Sichen, Cho Hyekyung P, Byers Frank W, Bubser Michael, Jones Carrie K, Niswender Colleen M, Wood Michael W, Engers Darren W, Wu Dedong, Brandon Nicholas J, Duggan Mark E, Conn P Jeffrey, Bridges Thomas M, Lindsley Craig W
机构信息
Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA.
出版信息
Bioorg Med Chem Lett. 2017 Jun 1;27(11):2296-2301. doi: 10.1016/j.bmcl.2017.04.043. Epub 2017 Apr 13.
Abstract
This letter describes the further chemical optimization of the 5-amino-thieno[2,3-c]pyridazine series (VU0467154/VU0467485) of M positive allosteric modulators (PAMs), developed via iterative parallel synthesis, culminating in the discovery of the non-human primate (NHP) in vivo tool compound, VU0476406 (8p). VU0476406 is an important in vivo tool compound to enable translation of pharmacodynamics from rodent to NHP, and while data related to a Parkinson's disease model has been reported with 8p, this is the first disclosure of the optimization and discovery of VU0476406, as well as detailed pharmacology and DMPK properties.
摘要
本信函描述了通过迭代平行合成开发的M型正变构调节剂（PAM）的5-氨基-噻吩并[2,3-c]哒嗪系列（VU0467154/VU0467485）的进一步化学优化，最终发现了非人类灵长类动物（NHP）体内工具化合物VU0476406（8p）。VU0476406是一种重要的体内工具化合物，可实现药效学从啮齿动物到NHP的转化，虽然已经报道了与帕金森病模型相关的8p数据，但这是VU0476406优化和发现以及详细药理学和药物代谢动力学性质的首次披露。
相似文献
1
Optimization of M positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.
Bioorg Med Chem Lett. 2017 Jun 1;27(11):2296-2301. doi: 10.1016/j.bmcl.2017.04.043. Epub 2017 Apr 13.
2
Challenges in the development of an M PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.
Bioorg Med Chem Lett. 2017 Jan 15;27(2):171-175. doi: 10.1016/j.bmcl.2016.11.086. Epub 2016 Nov 30.
3
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.
ACS Chem Neurosci. 2014 Oct 15;5(10):920-42. doi: 10.1021/cn500128b. Epub 2014 Aug 19.
4
The discovery of VU0486846: steep SAR from a series of M PAMs based on a novel benzomorpholine core.
Bioorg Med Chem Lett. 2018 Jul 1;28(12):2175-2179. doi: 10.1016/j.bmcl.2018.05.009. Epub 2018 May 5.
5
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.
Bioorg Med Chem Lett. 2016 Jul 1;26(13):3029-3033. doi: 10.1016/j.bmcl.2016.05.010. Epub 2016 May 5.
6
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.
Neuropharmacology. 2016 Mar;102:244-53. doi: 10.1016/j.neuropharm.2015.11.016. Epub 2015 Nov 23.
7
Discovery, Optimization, and Biological Characterization of 2,3,6-Trisubstituted Pyridine-Containing M Positive Allosteric Modulators.
ChemMedChem. 2019 May 6;14(9):943-951. doi: 10.1002/cmdc.201900088. Epub 2019 Mar 28.
8
Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides.
Bioorg Med Chem Lett. 2017 Dec 1;27(23):5179-5184. doi: 10.1016/j.bmcl.2017.10.053. Epub 2017 Oct 24.
9
Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.
Bioorg Med Chem Lett. 2017 Jul 1;27(13):2990-2995. doi: 10.1016/j.bmcl.2017.05.014. Epub 2017 May 6.
10
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M PAM VU0467154.
Neuropharmacology. 2018 Jan;128:492-502. doi: 10.1016/j.neuropharm.2017.07.013. Epub 2017 Jul 17.
引用本文的文献
1
Discovery of Pre-Clinical Candidate /: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy.
ACS Chem Neurosci. 2025 Jun 4;16(11):2141-2162. doi: 10.1021/acschemneuro.5c00277. Epub 2025 May 26.
2
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM).
ACS Chem Neurosci. 2024 Sep 24;15(20):3744-54. doi: 10.1021/acschemneuro.4c00465.
3
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.
Nat Rev Drug Discov. 2024 Oct;23(10):743-758. doi: 10.1038/s41573-024-01007-1. Epub 2024 Aug 14.
4
Discovery of VU6008677: A Structurally Distinct Tricyclic M Positive Allosteric Modulator with Improved CYP450 Profile.
ACS Med Chem Lett. 2024 Jul 3;15(8):1358-1366. doi: 10.1021/acsmedchemlett.4c00249. eCollection 2024 Aug 8.
5
Characterization of a Novel M4 PAM PET Radioligand [11C]PF06885190 in Nonhuman Primates (NHP).
Molecules. 2023 Jun 7;28(12):4612. doi: 10.3390/molecules28124612.
6
Discovery of structurally distinct tricyclic M positive allosteric modulator (PAM) chemotypes - Part 2.
Bioorg Med Chem Lett. 2021 Dec 1;53:128416. doi: 10.1016/j.bmcl.2021.128416. Epub 2021 Oct 26.
7
Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.
Trends Pharmacol Sci. 2019 Dec;40(12):1006-1020. doi: 10.1016/j.tips.2019.10.007. Epub 2019 Nov 8.
8
SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M PAMs.
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2224-2228. doi: 10.1016/j.bmcl.2019.06.032. Epub 2019 Jun 20.
9
Novel M positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands.
Bioorg Med Chem Lett. 2019 Feb 1;29(3):362-366. doi: 10.1016/j.bmcl.2018.12.039. Epub 2018 Dec 18.
10
Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M Muscarinic Receptor as a Novel Therapeutic Target.
J Pharmacol Exp Ther. 2018 May;365(2):291-300. doi: 10.1124/jpet.117.246991. Epub 2018 Mar 9.
本文引用的文献
1
Discovery of VU0467485/AZ13713945: An M PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.
ACS Med Chem Lett. 2016 Dec 16;8(2):233-238. doi: 10.1021/acsmedchemlett.6b00461. eCollection 2017 Feb 9.
2
Challenges in the development of an M PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.
Bioorg Med Chem Lett. 2017 Jan 15;27(2):171-175. doi: 10.1016/j.bmcl.2016.11.086. Epub 2016 Nov 30.
3
Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release.
Neuron. 2016 Sep 21;91(6):1244-1252. doi: 10.1016/j.neuron.2016.08.017. Epub 2016 Sep 8.
4
Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.
Bioorg Med Chem Lett. 2016 Sep 1;26(17):4282-6. doi: 10.1016/j.bmcl.2016.07.042. Epub 2016 Jul 21.
5
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.
Bioorg Med Chem Lett. 2016 Jul 1;26(13):3029-3033. doi: 10.1016/j.bmcl.2016.05.010. Epub 2016 May 5.
6
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
Neuron. 2015 Nov 18;88(4):762-73. doi: 10.1016/j.neuron.2015.10.039.
7
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice.
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14078-83. doi: 10.1073/pnas.1512812112. Epub 2015 Oct 27.
8
Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4).
J Biomol Screen. 2015 Aug;20(7):858-68. doi: 10.1177/1087057115581770. Epub 2015 Apr 15.
9
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.
ACS Chem Neurosci. 2014 Oct 15;5(10):920-42. doi: 10.1021/cn500128b. Epub 2014 Aug 19.
10
Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.
Neuropsychopharmacology. 2014 Jun;39(7):1578-93. doi: 10.1038/npp.2014.2. Epub 2014 Jan 20.
Zotero 插件